ライフサイエンスコーパス: phosphodiesterase

1 p75(NTR) expression and its interaction with phosphodiesterase.

2 lysis is increased by activation of the PDE5 phosphodiesterase.

3 ion increases resistance against snake venom phosphodiesterase.

4 e phosphorylation profile of a putative cGMP-phosphodiesterase.

5 o evolutionarily distinct phosphatases and a phosphodiesterase.

6 by increased activity of a c-di-GMP specific phosphodiesterase.

7 rain lacking enzymatic activity of the three phosphodiesterases.

8 mechanisms governing control of EAL c-di-GMP phosphodiesterases.

9 ein (ANK) and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) act to increase local extrac

10 AMP to AMP by ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) and an optimized assay for t

11 e report that ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is preferentially upregulate

12 g mutation in ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was identified in all patien

13 in (ANK), and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1).

14 nd evaluated for their inhibitory effects on phosphodiesterase 1 (PDE1) and phosphodiesterase 4 (PDE4

15 te inhibitory activities against tyrosyl-DNA phosphodiesterase 1 (TDP1) and tyrosyl-DNA phosphodieste

16 ngly, the CRISPR/Cas9 mutants of TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) are insensitive to CPT, and o

17 Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a molecular target for the

18 ted to the reduced expression of tyrosyl-DNA-phosphodiesterase 1 (TDP1), a DNA repair enzyme, in ATL

19 SMPD1 (sphingomyelin phosphodiesterase 1) was activated by ventilation and st

20 se, mammalian ectonucleotide pyrophosphatase/phosphodiesterase 1, Escherichia coli RppH, Legionella p

21 hosphatases (ecto-nucleotide pyrophosphatase/phosphodiesterases 1 and 3).

22 CD39, CD73, ecto-nucleotide pyrophosphatase/phosphodiesterases 1 and 3, CD157, CD38) for the acceler

23 t body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal gan

24 Phosphodiesterase 10A (PDE10A) is enriched in the striat

25 We report that changes of phosphodiesterase-10A (PDE10A) can map widespread functi

26 isorder has been genetically associated with Phosphodiesterase 11A (PDE11A), and lithium decreases PD

27 Here, we study the role of phosphodiesterase 11A4 (PDE11A4) in systems consolidatio

28 METHODS AND Pharmacological inhibition of phosphodiesterase 2 (BAY 60-7550, BAY) led to a signific

29 Phosphodiesterase 2 (PDE2) inhibitors increase the intra

30 Repair of such damage by tyrosyl DNA phosphodiesterase 2 (TDP2) could render cancer cells res

31 However, knockout of cellular 5' tyrosyl-DNA phosphodiesterase 2 (TDP2) did not markedly affect rcDNA

32 litates a proteasome-independent tyrosyl-DNA phosphodiesterase 2 (TDP2) hydrolase activity on stalled

33 Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a multifunctional protein

34 Tyrosyl-DNA phosphodiesterase 2 (TDP2) reverses Topoisomerase 2 DNA-

35 A phosphodiesterase 1 (TDP1) and tyrosyl-DNA phosphodiesterase 2 (TDP2), two enzymes that are involve

36 d breaks are rejoined in part by tyrosyl-DNA phosphodiesterase 2 (TDP2)-dependent non-homologous end-

37 Greater phosphodiesterase 2 abundance protects against arrhythmi

38 Endogenous phosphodiesterase 2 contributes to heart rate regulation

39 To explore the role of phosphodiesterase 2 in cardiac function, propensity to a

40 RATIONALE: Phosphodiesterase 2 is a dual substrate esterase, which

41 Myocardial phosphodiesterase 2 is upregulated in human heart failur

42 Activating myocardial phosphodiesterase 2 may, thus, represent a novel intrace

43 Conversely, ECG telemetry in heart-specific phosphodiesterase 2-transgenic (TG) mice showed a marked

44 protein kinase G and of the cGMP hydrolyzing phosphodiesterases 2 and 3.

45 We previously showed that 2',5'-phosphodiesterases (2',5'-PDEs) encoded by the prototypi

46 titis virus (MHV) and MERS-CoV, encode 2',5'-phosphodiesterases (2',5'-PDEs) that antagonize the OAS-

47 ration of a [1,2,4]triazolo[1,5-a]pyrimidine phosphodiesterase 2A (PDE2A) inhibitor arising from high

48 Phosphodiesterase 2A (PDE2A) inhibitors have been report

49 ependent on the activity of cAMP-hydrolyzing phosphodiesterase 3 (PDE3).

50 In contrast, treating RBCs with a phosphodiesterase 3 inhibitor did not affect ATP release

51 diamide (cell-stiffening agent), cilostazol (phosphodiesterase 3 inhibitor), or vehicle control.

52 DNMDP induces complex formation between phosphodiesterase 3A (PDE3A) and schlafen family member

53 The phosphodiesterase 3A (PDE3A) gene encodes a PDE that reg

54 We recently implicated the gene encoding phosphodiesterase 3A (PDE3A); however, in vivo modeling

55 thway where an unexpected estrogen receptor, phosphodiesterase 3A, allows its partner Schlafen-12 to

56 y targeted inactivation of cyclic nucleotide phosphodiesterase 3b (Pde3b) gene, which encodes PDE3B,

57 tein kinase G (PKG), protein kinase A (PKA), phosphodiesterase 3B (PDE3B), and a membrane-permeable c

58 Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage o

59 al repression of the cAMP-hydrolyzing enzyme phosphodiesterase-3b (Pde3b) by microRNA-142-5p (miR-142

60 ry effects on phosphodiesterase 1 (PDE1) and phosphodiesterase 4 (PDE4) as well as for their inhibito

61 Inhibitors of cAMP-phosphodiesterase 4 (PDE4) exert a number of promising t

62 ure leads to up-regulation of cAMP-degrading phosphodiesterase 4 (PDE4) expression, which compromises

63 The phosphodiesterase 4 (PDE4) family coordinates the degrad

64 Inhibition of cyclic AMP (cAMP)-specific phosphodiesterase 4 (PDE4) has been proposed as a potent

65 Phosphodiesterase 4 (PDE4) inhibition restores the suppr

66 Crisaborole, a topical phosphodiesterase 4 (PDE4) inhibitor, became available i

67 Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing en

68 scaffolding protein DISC1 and cAMP-degrading phosphodiesterase 4 (PDE4) to regulate PDE4 activity.

69 ed to a dual inhibition of p38alpha MAPK and phosphodiesterase 4 (PDE4), and the potential benefits a

70 P elevations in the PFC secondary to reduced phosphodiesterase 4 activity present in Disc1 deficiency

71 ighting the therapeutic utility of targeting phosphodiesterase 4 in patients with AD.

72 Crisaborole ointment 2% is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-

73 ial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviole

74 Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide

75 /23, IL-17, and p19IL-23, as well as an oral phosphodiesterase 4 inhibitor.

76 vanced small molecule apremilast, which is a phosphodiesterase 4 inhibitor.

77 atory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibitors in pe

78 Cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) enzymes degrade cAMP and unde

79 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

80 ctivity by using (11)C-(R)-rolipram to image phosphodiesterase-4 (PDE4) in unmedicated MDD patients a

81 Here we investigated whether 3 phosphodiesterase-4 (PDE4) inhibitors (rolipram, roflumi

82 UD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inh

83 As a selective phosphodiesterase-4 inhibitor, rolipram also exhibits th

84 bolic stability, and lacked activity against phosphodiesterase-4.

85 991 increases the Vmax of cyclic nucleotide phosphodiesterase 4B (PDE4B) without affecting intracell

86 ophosphate; cAMP)-hydrolyzing protein PDE4B (phosphodiesterase 4B) is a key negative regulator of car

87 Osthole inhibited phosphodiesterase 4D (PDE4D) activity to amplify autocri

88 ive regulation of cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) and the regulatory subunit

89 e production without affecting cAMP-mediated phosphodiesterase 4D (PDE4D) gene expression, phospho-cA

90 in-induced phosphorylation and expression of phosphodiesterase 4D (PDE4D) through transactivation of

91 CC2D1A is known to regulate phosphodiesterase 4D (PDE4D), which regulates cyclic ade

92 t, one genomewide significant hit located in phosphodiesterase 4D, cAMP-specif (PDE4D) and 26 SNPs wi

93 therefore explored if BPN14770, a prototypic phosphodiesterase-4D negative allosteric modulator (PDE4

94 ntegrin alpha5, which recruits and activates phosphodiesterase 4D5 (PDE4D5) by inducing its dephospho

95 nitric oxide by restraining the activity of phosphodiesterase 5 (PDE5) by acting as a substrate adap

96 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine m

97 protein phosphatase 2 A abundance following phosphodiesterase 5 inhibition.

98 ric oxide donor sodium nitroprusside and the phosphodiesterase 5 inhibitor sildenafil compared with h

99 We found that, sildenafil, a phosphodiesterase 5 inhibitor, induced mitochondrial bio

100 eating various cell lines with inhibitors of phosphodiesterase 5 or stimulators of soluble guanylyl c

101 il is a clinically relevant drug that blocks phosphodiesterase 5 with high specificity and is used to

102 oth muscle cells (PASMCs), and inhibition of phosphodiesterase-5 (PDE5) has been shown to suppress TR

103 Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor causing accumulatio

104 Phosphodiesterase-5 (PDE5) inhibitors are suggested to h

105 S-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 inhibitors, respectively) as

106 nNOS(S1412A) ileum expressed less phosphodiesterase-5 and was more sensitive to relaxation

107 Because phosphodiesterase-5 inhibition leads to improved lung hi

108 h preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Statu

109 Phosphodiesterase-5 inhibition with sildenafil compared

110 Treatment of mice with the phosphodiesterase-5 inhibitor vardenafil (Levitra) mobil

111 e signaling pathway, we assessed whether the phosphodiesterase-5 inhibitor, sildenafil (SIL), could a

112 The phosphodiesterase-5 inhibitor, sildenafil, potentiates N

113 Use of phosphodiesterase-5 inhibitors (PDE5i) for groups 2 and

114 Selective pulmonary vasodilators, like phosphodiesterase-5 inhibitors (PDE5i), are used off-lab

115 ered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors and beneficial actions of

116 Phosphodiesterase-5 inhibitors and other cyclic guanosin

117 Phosphodiesterase-5 inhibitors enhanced proteasomal degr

118 rate that the increase of cGMP levels by the phosphodiesterase-5 inhibitors sildenafil and vardenafil

119 ailable-ie, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclas

120 MP/PKG2 signaling, and can be targeted using phosphodiesterase-5 inhibitors.

121 ivation and inhibition of the cGMP-degrading phosphodiesterase-5, ischemic preconditioning, and postc

122 The target enzyme, phosphodiesterase 5A (PDE5A), was found to be expressed

123 e monophosphate is mainly hydrolyzed by PDE (phosphodiesterases) 5a and 9a.

124 Phosphodiesterase 5A1 (PDE5) is a key target for treatin

125 A2 (PLA2) and ectonucleotide pyrophophatase/phosphodiesterase 6 (ENPP6)-act in sequence upon phospha

126 Photoreceptor phosphodiesterase 6 (PDE6) is the central effector of th

127 important biological role as a chaperone of phosphodiesterase 6 (PDE6), an effector enzyme of the vi

128 L1) is essential for the correct assembly of phosphodiesterase 6 (PDE6), which is a pivotal effector

129 it (Galpha(T).GTP) and the cyclic GMP (cGMP) phosphodiesterase 6 (PDE6), which stimulates cGMP hydrol

130 e effector enzyme of phototransduction, cGMP phosphodiesterase 6 (PDE6).

131 ciation of isoprenylated transducin and cone phosphodiesterase 6 (PDE6alpha') with photoreceptor memb

132 We also found that calmodulin and phosphodiesterase 6 delta (PDE6delta), but not galectin3

133 The phosphodiesterase 6 delta subunit (PDE6delta) shuttles s

134 on the BBSome and the prenyl-binding protein phosphodiesterase 6 subunit delta (PDE6D), respectively,

135 Phosphodiesterase-6 (PDE6) is key to both phototransduct

136 Phosphodiesterase-6 (PDE6) plays a central role in both

137 to mislocalization of rhodopsin, prenylated phosphodiesterase-6 (PDE6), and intraflagellar transport

138 ion-10 (rd10) mouse, which has a mutation in Phosphodiesterase-6b (Pde6b) that causes a phenotype mim

139 function through regulation of a key enzyme, phosphodiesterase 6beta (Pde6beta), involved in modulati

140 We identified phosphodiesterase 7B (PDE7B) as a bona fide miR-200c tar

141 Phosphodiesterase-9 (PDE9) reduces natriuretic peptide (

142 hemodynamic, endocrine, and renal effects of phosphodiesterase-9 inhibition (PDE9-I).

143 and the lipid-modifying enzyme sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) in radiation-in

144 The lipid-modulating enzyme sphingomyelin phosphodiesterase acid-like 3B (SMPDL3b) is a key determ

145 Sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) is a lipid raft

146 Sphingomyelin phosphodiesterase, acid-like 3A (SMPDL3A) is a member of

147 used the models to test the hypothesis that phosphodiesterases act as functional barriers to diffusi

148 d state holds the C-terminal EAL enzyme in a phosphodiesterase-active conformation.

149 They combine mono-ADP-ribosylation and phosphodiesterase activities to attach ubiquitin onto su

150 itionally, we noted that DeltaN-TDP2 retains phosphodiesterase activity and is protective against eto

151 ivates CFTR in Xenopus oocytes by inhibiting phosphodiesterase activity and subsequent stimulation of

152 s observe "buffered diffusion" and establish phosphodiesterase activity can organize cAMP nanodomains

153 Although most well-known for its phosphodiesterase activity removing stalled topoisomeras

154 ortholog, we show that yeast Usb1 has cyclic phosphodiesterase activity that leaves a terminal 3' pho

155 Further, Csx3 harbors cyclic oligonucleotide phosphodiesterase activity that quickly degrades this cA

156 sterase domain displays catalytic, saturable phosphodiesterase activity toward the dinucleotide 2',3'

157 otide signalling, resulting from compromised phosphodiesterase activity, as well as alterations in re

158 to phosphoribosylation by enzymes possessing phosphodiesterase activity, such as snake venom phosphod

159 ay be related to a differential switching in phosphodiesterase activity.

160 ependent on proteasomal degradation and TDP2 phosphodiesterase activity.

161 that CodY consists of a GAF (cGMP-stimulated phosphodiesterases, adenylate cyclases, FhlA) domain tha

162 escribe a crystalline form of the cyclic GMP phosphodiesterases/adenylyl cyclase/FhlA (GAF) domain fr

163 dels predict that under realistic conditions phosphodiesterases alone were insufficient to generate s

164 Trl1 is composed of C-terminal cyclic phosphodiesterase and central polynucleotide kinase doma

165 l defined electron density for p261C and the phosphodiesterase and oligonucleotide/oligosaccharide-bi

166 lerated rate of decay of the effector enzyme phosphodiesterase and perhaps also of activated visual p

167 iated mainly by two glycerophosphoryldiester phosphodiesterases and three patatin-like phospholipases

168 Phosphodiesterases are proving to be fruitful targets fo

169 mutation on a germline insertion in PDE1A, a phosphodiesterase associated with melanoma.

170 A cGMP-activated phosphodiesterase (AtCN-PDE1) was responsible for the UV

171 e, we demonstrate that Plasmodium falciparum phosphodiesterase beta (PDEbeta) hydrolyses both cAMP an

172 t starvation triggers c-di-GMP hydrolysis by phosphodiesterase BifA, releasing inhibition of protease

173 ulatory protein coronin 1 that regulates the phosphodiesterase/cAMP pathway and modulates T cell resp

174 Sts-1 also had phosphodiesterase catalytic activity toward a 5-mer RNA

175 he myelin protein 2'-3'-cyclic nucleotide 3'-phosphodiesterase (CNP) are associated with the schizoph

176 In cells lacking 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNPase; an enzyme that metabolizes 2'

177 Trl1 is composed of C-terminal cyclic phosphodiesterase (CPD) and central GTP-dependent polynu

178 kinase (KIN) domain; and a C-terminal cyclic phosphodiesterase (CPD) domain.

179 scerevisiae Usb1 has additional 2',3' cyclic phosphodiesterase (CPDase) activity, which converts the

180 ulatory protein coronin 1 that regulates the phosphodiesterase/cyclic adenosine monophosphate pathway

181 main and for the linker connecting it to the phosphodiesterase domain.

182 ates the activity of diguanylate cyclase and phosphodiesterase domains acting on cyclic-di-GMP.

183 e studied the EAL signature motif-containing phosphodiesterase domains from the Pseudomonas aeruginos

184 Several unique families of phosphodiesterases exist, and certain families are clini

185 of chronic hypoxia prevented the increase in phosphodiesterase expression (72.5 +/- 22.4%), protected

186 , particularly PknA in trans-phosphorylating phosphodiesterase from Mycobacterium tuberculosis (mPDE)

187 t the HD-GYP enzyme PmxA is a cGAMP-specific phosphodiesterase (GAP) that promotes resistance to osmo

188 Six-transmembrane glycerophosphodiester phosphodiesterases (GDEs) are emerging as central regula

189 rolled by the synthase DacA and two putative phosphodiesterases, GdpP and Pde2.

190 entified a strong G x sex interaction at the phosphodiesterase gene 4D locus (PDE4D), a known asthma-

191 does so in a manner that depends on the gdpP phosphodiesterase gene.

192 All restriction enzymes examined are phosphodiesterases generating 3-OH and 5-P ends, but one

193 s at the 3'UTR and the mRNA stability of two phosphodiesterase genes (PDE1C and PDE4B), FTO augmented

194 Although the two cAMP phosphodiesterase genes PDE1 and PDE2 had overlapping fu

195 We show here that the exolytic sn-glycerol-3-phosphodiesterase GlpQ can discriminate between B. subti

196 Phosphodiesterases have emerged as attractive molecular

197 [p.Phe334Leu] in one individual), encoding a phosphodiesterase highly and selectively present in MSNs

198 Tyrosyl DNA-phosphodiesterase I (TDP1) repairs type IB topoisomerase

199 ds in the presence or absence of tyrosyl DNA phosphodiesterase I (TDP1); a key TOP1-mediated protein-

200 Tyrosyl DNA phosphodiesterase II (TDP2) is a recently discovered enz

201 potential selective inhibitor of tyrosyl DNA phosphodiesterase II is performed.

202 his study, we assessed whether cilostazol, a phosphodiesterase III inhibitor, could protect against t

203 s an emerging role for the PDE4 subfamily of phosphodiesterases in malignancy.

204 predict the presence of non-canonical HD-GYP phosphodiesterases in many bacterial species, including

205 input is filtered by adenylyl cyclase 1 and phosphodiesterases in this pathway such that cAMP/PKA on

206 mammalian cell line (CHO cells) and used the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine

207 Papaverine is a well-known phosphodiesterase inhibitor and also modifies the mitoge

208 or environmental acidification, while a cGMP-phosphodiesterase inhibitor circumvents egress repressio

209 Targeting these pathways by using the phosphodiesterase inhibitor dipyridamole restored immune

210 gondii In doing so, we took advantage of the phosphodiesterase inhibitor zaprinast, which we show act

211 Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia

212 creased cAMP levels within 3 minutes without phosphodiesterase inhibitors by measuring real-time cAMP

213 y 36,000 compounds, we identified a class of phosphodiesterase inhibitors that suppress let-7 targets

214 s confirmed by adenylate cyclase activators, phosphodiesterase inhibitors, and most notably by stimul

215 ished by deltarasin, an inhibitor of the Ras-phosphodiesterase interaction, or by simultaneous deplet

216 ng by isoform-specific displacement of bound phosphodiesterase is demonstrated to increase retinal ga

217 gative feedback regulation of cAMP levels by phosphodiesterase is well-established in eukaryotic cell

218 easurements of various enzymatic activities (phosphodiesterase, kinase, bacterial translation) under

219 in hydrolyzing cellular cAMP, we utilized a phosphodiesterase knock-out Escherichia coli strain, Del

220 denylyl cyclase bPAC and the light-activated phosphodiesterase LAPD, and the cAMP biosensor mlCNBD-FR

221 a(2+) oscillations, whereas Ca(2+)-sensitive phosphodiesterases maintain out-of-phase oscillations ou

222 sphodiesterase activity, such as snake venom phosphodiesterase, mammalian ectonucleotide pyrophosphat

223 cyclic diguanosine monophosphate (c-di-GMP) phosphodiesterase MbaA.

224 se belongs to the nucleotide pyrophosphatase/phosphodiesterase (NPP) family, the members of which hyd

225 Xanthomonas citri nucleotide pyrophosphatase/phosphodiesterase (NPP)] and distinct differences from t

226 ctors, including expression of any number of phosphodiesterases (of which there are 24 genes plus spi

227 eviously characterised two-metal binding EAL-phosphodiesterases, PA3825(EAL) in complex with pGpG pro

228 ARCP-1 binds the Ca(2+)-dependent phosphodiesterase PDE-1 and co-localizes PDE-1 with mole

229 The effects of phosphodiesterase (PDE) 4 inhibitors on gene expression

230 As part of our effort in identifying phosphodiesterase (PDE) 4B-preferring inhibitors for the

231 Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster stat

232 Using the FRET approach and in vitro phosphodiesterase (PDE) activity assays, we show that at

233 systematic analysis is presented of the 220 phosphodiesterase (PDE) catalytic domain crystal structu

234 VP3 from homologous RVs relies on its 2'-5'-phosphodiesterase (PDE) domain to counteract RNase L-med

235 ligases harbor a highly homologous catalytic phosphodiesterase (PDE) domain.

236 Phosphodiesterase (PDE) enzymes are known to control cyc

237 His-associated (DHH/DHHA1) domain-containing phosphodiesterase (PDE) GdpP, S. aureus produces a secon

238 ntification of novel 3',5'-cyclic nucleotide phosphodiesterase (PDE) inhibitors, concentrating on bot

239 equired for social memory formation, but the phosphodiesterase (PDE) involved remains unknown.

240 lecules modulating the nitric oxide (NO)-GMP-phosphodiesterase (PDE) pathway, the evaluation of nitra

241 V]) nonstructural protein 2 (ns2) is a 2',5'-phosphodiesterase (PDE) that cleaves 2-5A, thereby antag

242 Here, we show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)

243 Cyclic nucleotide phosphodiesterases (PDE) break down cyclic nucleotides s

244 regulators of intracellular cAMP gradients, phosphodiesterases (PDE) mediate fundamental aspects of

245 Inhibition of type 4 phosphodiesterase (PDE4) and elevation of cyclic adenosi

246 Type 4 phosphodiesterases (PDE4) are key cAMP-hydrolyzing enzym

247 ubstrate channeling" from the channel to the phosphodiesterase PDE5.

248 Regulation of photoreceptor phosphodiesterase (PDE6) activity is responsible for the

249 rictly controlled by the opposing actions of phosphodiesterase (PDE6) and retinal guanylyl cyclases (

250 le assembly of the retinal cyclic GMP (cGMP) phosphodiesterase (PDE6) holoenzyme.

251 Photoreceptor phosphodiesterase (PDE6) is the central effector enzyme

252 cilitate the stable assembly of retinal cGMP phosphodiesterase, PDE6.

253 Following the discovery that flagellar phosphodiesterase PDEB1 is required for trypanosomes to

254 es (activation phase) and cAMP hydrolysis by phosphodiesterases (PDEs) (termination phase).

255 the biofilm lifestyle, c-di-GMP hydrolysing phosphodiesterases (PDEs) have been identified as key ta

256 xplain signaling specificity, cAMP-degrading phosphodiesterases (PDEs) have been suggested to confine

257 ic functions for different cyclic nucleotide phosphodiesterases (PDEs) have not yet been identified i

258 lases (DGCs) CdgB and CdgC, and the c-di-GMP phosphodiesterases (PDEs) RmdA and RmdB, are poorly unde

259 Phosphodiesterases (PDEs), enzymes that degrade 3',5'-cy

260 The cAMP-degrading enzymes, phosphodiesterases (PDEs), localise to specific subcellu

261 Cyclic nucleotide phosphodiesterases (PDEs), through degradation of cyclic

262 cGMP-specific phosphodiesterases (PDEs), which degrade cGMP to guanosi

263 -coupled receptors (GPCRs) and attenuated by phosphodiesterases (PDEs).

264 any of the individual c-di-GMP synthases or phosphodiesterases (PDEs).

265 stent with reported effects of inhibition of phosphodiesterases (PDEs).

266 Furthermore, we identified a phosphodiesterase, PdeV, whose loss promotes biofilm for

267 l amplification at the pigment-to-transducin/phosphodiesterase phototransduction step, especially in

268 e adenylate cyclases ACG or ACR, or the cAMP phosphodiesterase RegA.

269 ingomyelin synthases (SMS) and sphingomyelin phosphodiesterase (SMase) enzymes may play roles in SM d

270 FAM151 proteins are members of the PLC-like phosphodiesterase superfamily.

271 hatidylserine synthase (PSS) and tyrosyl-DNA phosphodiesterase (TDP), and conserved catalytic residue

272 clease MUS81 and the protease WSS1A, and the phosphodiesterase TDP1 as backup.

273 yme for TOP1cc resolution is the tyrosyl-DNA phosphodiesterase (TDP1), which hydrolyses the bond that

274 The catalytic activity of an artificial phosphodiesterase that combines a ligated metal ion (Cu(

275 mutant phenotypes were gdpP, which encodes a phosphodiesterase that degrades the second messenger cyc

276 tify the AtaC protein as a c-di-AMP-specific phosphodiesterase that is also conserved in pathogens su

277 VieA is a cyclic diguanylate phosphodiesterase that modulates biofilm development and

278 Tdp1 and Tdp2 are two tyrosyl-DNA phosphodiesterases that can repair damaged DNA resulting

279 d DON production, and Pde2 is the major cAMP phosphodiesterase to negatively regulate DON biosynthesi

280 down of sGCbeta1 or upon overexpression of a phosphodiesterase to prevent cGMP buildup.

281 ore, attenuated cGMP signals led to impaired phosphodiesterase two dependent negative cGMP-to-cAMP cr

282 Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been ef

283 Phosphodiesterase type 4 (PDE4) is a family of enzymes t

284 ignaling cascade, leading to upregulation of phosphodiesterase type 4 (PDE4), which catalyzes the hyd

285 -controlled Phase III clinical trials of the phosphodiesterase type 4 inhibitor apremilast in psorias

286 Laboratory evidence suggests that reduced phosphodiesterase type 5 (PDE5) expression increases the

287 ng treatment with oral sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vas

288 clic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role

289 ng specificity remarkably similar to that of phosphodiesterase type 5 (PDE5), an enzyme that catalyze

290 eroxide dismutase (60.7 +/- 6.3%), increased phosphodiesterase type 5 expression (167 +/- 13.7%) and

291 evented by elevation of cGMP levels with the phosphodiesterase type 5 inhibitor sildenafil.

292 Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the acti

293 In men, medication such as phosphodiesterase type 5 inhibitors may be beneficial, a

294 st-LT, and endothelin receptor antagonist or phosphodiesterase type 5 inhibitors were continued in 15

295 uding soluble guanylate cyclase stimulators, phosphodiesterase type 5 inhibitors, sodium nitrite and

296 Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled

297 ance of low c-di-GMP concentrations by these phosphodiesterases was required to promote survival with

298 Three sensor phosphodiesterases were identified as critical to mainta

299 late cyclase with forskolin or inhibition of phosphodiesterase with rolipram produced similar effects

300 n increase in the rate of decay of activated phosphodiesterase, with perhaps also an increase in the